Randomized Trialhigh evidence
Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet (London, England)·May 2, 2026·PMID 42030965
Why it mattersCemdisiran offers a novel mechanism—siRNA-mediated C5 inhibition—with convenient quarterly subcutaneous dosing, potentially expanding complement-targeted treatment options beyond current intravenous C5 inhibitors for AChR antibody-positive generalized myasthenia gravis.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled